Madrigal Pharmaceuticals, Inc. Common Stock Earnings Dividend

Madrigal Pharmaceuticals, Inc. Common Stock’s revenue jumped 126.84% since last year same period to $311.34Mn in the Q1 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated -3.04% fall in its revenue since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s net profit fell -28.88% since last year same period to $-94.39Mn in the Q1 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated -61.15% fall in its net profits since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 43.18% since last year same period to -30.32% in the Q1 2026. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. Common Stock has generated -66.19% fall in its net profit margins since last 3-months.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -2.34 - a 43.48% jump from last quarter’s estimates.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -2.34.

Madrigal Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 58.43% since last year same period to -1.38 in the Q1 2026. This indicates that the Madrigal Pharmaceuticals, Inc. Common Stock has generated 58.43% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Madrigal Pharmaceuticals, Inc. Common Stock’s return on assets (ROA) stands at -0.18.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Madrigal Pharmaceuticals, Inc. Common Stock’s return on equity (ROE) stands at -0.49.